Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SYK
SYK logo

SYK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
333.990
Open
328.900
VWAP
329.42
Vol
2.57M
Mkt Cap
126.41B
Low
324.540
Amount
847.66M
EV/EBITDA(TTM)
19.44
Total Shares
383.36M
EV
136.25B
EV/OCF(TTM)
25.35
P/S(TTM)
4.97
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
Show More

Events Timeline

(ET)
2026-05-26
06:20:00
Stryker Launches Pangea Plating System in Europe
select

News

CNBC
6.5
07-07CNBC
UBS Recommends Low Volatility Stocks to Stabilize Portfolios
  • Strong Market Performance: The S&P 500 index rose 9.6% in the first half of 2026, achieving nearly a 15% increase in the second quarter, marking its best quarterly performance since 2020, despite investors facing turbulence including the onset of the Iran war.
  • Low Volatility Stock Recommendations: UBS highlights the lagging performance of low volatility stocks as capital has concentrated in AI-driven sectors, suggesting investors focus on high-quality companies with resilient fundamentals and attractive valuations to mitigate portfolio swings.
  • Positive Outlook for Yum Brands: The parent company of Taco Bell and KFC, Yum Brands, is expected to achieve its highest cash flow return on investment by 2027, with plans for international expansion and a KFC loyalty program driving topline growth, and its stock has risen over 10% this year.
  • Significant Potential for Lockheed Martin: While UBS maintains a neutral stance on Lockheed Martin, it anticipates a positive reaction to its upcoming second-quarter earnings report, with a $35 billion defense contract potentially boosting 2026 performance, and the stock has increased by about 10%.
NASDAQ.COM
9.5
07-02NASDAQ.COM
Stryker to Release Q2 2026 Financial Results
  • Financial Performance Growth: In Q1 2026, Stryker's net sales increased by 2.6% year-over-year to $6.02 billion, primarily driven by strong performance in the MedSurg and Neurotechnology segments, which generated $3.21 billion, while Orthopaedics contributed $2.81 billion, indicating the company's sustained growth potential in the medical technology sector.
  • Profitability Improvement: The net earnings for Q1 rose by 13.9% to $0.74 billion, translating to $1.93 per share, compared to $0.65 billion and $1.69 per share in the previous year, reflecting effective strategies in cost control and market demand management.
  • Future Outlook: Stryker anticipates organic net sales growth of 8.0% to 9.5% for the full year 2026, with adjusted earnings per diluted share expected to range between $14.90 and $15.10, demonstrating the company's confidence in future market performance and proactive growth strategies.
  • Historical Performance Review: In Q2 2025, Stryker's consolidated net sales increased by 11.1% year-over-year to $6.022 billion, with MedSurg and Neurotechnology sales rising by 17.3%, showcasing the company's strong competitive position in the medical device market.
NASDAQ.COM
9.5
06-29NASDAQ.COM
Stryker Shares Surge 5.3% on Analyst Upgrade and Growth Prospects
  • Significant Price Surge: Stryker (SYK) shares rose 5.3% in the last trading session to close at $332.71, with trading volume significantly exceeding normal levels, reflecting renewed investor optimism regarding the company's long-term growth prospects.
  • Analyst Upgrade: A recent upgrade to 'Outperform' by analysts has bolstered investor confidence, alongside management's reaffirmation of full-year guidance, indicating a recovery from temporary cyber disruptions.
  • Strong Earnings Expectations: Stryker is expected to report quarterly earnings of $3.49 per share, representing an 11.5% year-over-year increase, with revenues projected at $6.56 billion, up 8.9%, highlighting the company's robust performance in the medical device sector.
  • Earnings Estimate Revision: Although the consensus EPS estimate has been slightly revised lower, the correlation between earnings estimate trends and stock price movements suggests that investors should monitor SYK's future performance to determine if this price increase can be sustained.
PRnewswire
7.5
06-24PRnewswire
Stryker Partners with Golfer Shane Lowry to Promote Joint Replacement Awareness
  • Brand Ambassador Partnership: Stryker has announced a partnership with globally recognized golfer Shane Lowry, naming him a brand ambassador for its Joint Replacement division, leveraging Lowry's personal experiences to raise awareness about joint pain and the role of caregivers.
  • Personal Story Sharing: As a caregiver to his father, Lowry has witnessed the impact of joint pain on patients and families, and by sharing his story, he aims to encourage more caregivers to actively engage in their loved ones' treatment and recovery processes.
  • Global Awareness Campaign: This collaboration will utilize media, social channels, and educational initiatives to elevate the importance of caregivers in the joint replacement journey, helping them better understand treatment options and recovery processes.
  • Patient Impact: Katherine Truppi, president of Stryker's Joint Replacement division, emphasized that joint replacement is more than surgery; it is a personal journey affecting both patients and their supporters, and Lowry's story authentically conveys this perspective to help more people seek support.
NASDAQ.COM
4.5
06-18NASDAQ.COM
IYH ETF 52-Week Price Range Analysis
  • Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
  • Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
  • ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
  • Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
CNBC
6.5
06-18CNBC
Jim Cramer's Insights on Multiple Stocks
  • Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
  • Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
  • Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
  • Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
Wall Street analysts forecast SYK stock price to rise
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
390.00
Averages
430.32
High
465.00
Current: 0.000
sliders
Low
390.00
Averages
430.32
High
465.00
Evercore ISI
Outperform
to
Outperform
downgrade
$355 -> $350
AI Analysis
2026-07-06
New
Reason
Evercore ISI
Price Target
$355 -> $350
AI Analysis
2026-07-06
New
downgrade
Outperform
to
Outperform
Reason
Evercore ISI lowered the firm's price target on Stryker to $350 from $355 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.
BofA
Buy
maintain
$450 -> $380
2026-06-12
Reason
BofA
Price Target
$450 -> $380
2026-06-12
maintain
Buy
Reason
BofA lowered the firm's price target on Stryker to $380 from $450 and keeps a Buy rating on the shares. Noting that the firm's services team continues to highlight a lower utilization environment, the analyst wants to take a more conservative view on 2027 medtech company estimates given valuations are already reflecting utilization risk, the analyst tells investors. The analyst, who is also assuming inflation is more of a headwind in 2027 with less margin expansion for medtech, lowers 2027 estimates across the firm's larger-cap coverage where there's exposure to utilization and inflation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SYK
Unlock Now

Valuation Metrics

The current forward P/E ratio for Stryker Corp (SYK.N) is 21.79, compared to its 5-year average forward P/E of 26.01. For a more detailed relative valuation and DCF analysis to assess Stryker Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.01
Current PE
21.79
Overvalued PE
28.47
Undervalued PE
23.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
21.32
Current EV/EBITDA
21.10
Overvalued EV/EBITDA
23.09
Undervalued EV/EBITDA
19.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.24
Current PS
4.23
Overvalued PS
5.83
Undervalued PS
4.65

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks will decrease this week
Intellectia · 42 candidates
Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossDownMA5, PriceBelowMA20Week Price Change Pct: $-100.00 - $-2.00One Week Rise Prob: 0 - 40One Week Predict Return: -100.0% - -2.0%
Ticker
Name
Market Cap$
top bottom
SYK logo
SYK
Stryker Corp
125.81B
VTR logo
VTR
Ventas Inc
39.03B
VEEV logo
VEEV
Veeva Systems Inc
29.25B
RYTM logo
RYTM
Rhythm Pharmaceuticals Inc
5.64B
DBX logo
DBX
Dropbox Inc
5.58B
CRSP logo
CRSP
CRISPR Therapeutics AG
4.46B
top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
ok the us stocks instead
Intellectia · 197 candidates
Price: >= $5.00Market Cap Category: large, mid, smallGross Margin: >= 20.00Net Margin: >= 5.00Debt Equity: <= 150List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Annual Eps Yoy Growth: >= 5.0%Annual Revenue Yoy Growth: >= 5.0%
Ticker
Name
Market Cap$
top bottom
KLAC logo
KLAC
KLA Corp
199.83B
CRM logo
CRM
Salesforce Inc
182.52B
APH logo
APH
Amphenol Corp
179.54B
SCCO logo
SCCO
Southern Copper Corp
178.81B
SCHW logo
SCHW
Charles Schwab Corp
166.81B
SYK logo
SYK
Stryker Corp
148.28B
which stock to pick tomorrow
Intellectia · 158 candidates
Relative Vol: >= 1.15Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
1.02T
AMD logo
AMD
Advanced Micro Devices Inc
406.68B
CAT logo
CAT
Caterpillar Inc
302.02B
AMGN logo
AMGN
Amgen Inc
185.02B
SYK logo
SYK
Stryker Corp
138.80B
ETN logo
ETN
Eaton Corporation PLC
131.26B
which stock to buy for this week earnings
Intellectia · 213 candidates
Market Cap: >= 1000.00MBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
MCD logo
MCD
McDonald's Corp
217.70B
SHEL logo
SHEL
Shell PLC
209.17B
AMGN logo
AMGN
Amgen Inc
185.02B
SPGI logo
SPGI
S&P Global Inc
160.84B
PFE logo
PFE
Pfizer Inc
147.20B
SYK logo
SYK
Stryker Corp
138.80B
strong buy stocks today
Intellectia · 61 candidates
Analyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Rsi 14: 30 - 70Week Price Change Pct: >= $0.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.45T
LLY logo
LLY
Eli Lilly and Co
1.02T
UNH logo
UNH
UnitedHealth Group Inc
315.01B
KO logo
KO
Coca-Cola Co
309.76B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
C logo
C
Citigroup Inc
198.97B
Stocks that trade in a channel
Intellectia · 222 candidates
Beta: LowRiskWeekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA20Support Resistance Relationship: PriceAroundResistance, PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
WMT logo
WMT
Walmart Inc
951.32B
BABA logo
BABA
Alibaba Group Holding Ltd
402.68B
CVX logo
CVX
Chevron Corp
335.71B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
MRK logo
MRK
Merck & Co Inc
275.78B

Whales Holding SYK

P
Pallas Capital Advisors LLC
Holding
SYK
+27.63%
3M Return
B
Bellevue Asset Management AG
Holding
SYK
+19.99%
3M Return
K
Kensico Capital Management Corp.
Holding
SYK
+18.99%
3M Return
B
Beacon Investment Advisory Services, Inc.
Holding
SYK
+17.67%
3M Return
C
Colonial Trust Advisors, Inc.
Holding
SYK
+12.50%
3M Return
T
T. Rowe Price Group, Inc.
Holding
SYK
+12.25%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Stryker Corp (SYK) stock price today?

The current price of SYK is 329.74 USD — it has increased 1.54

What is Stryker Corp (SYK)'s business?

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.

What is the price predicton of SYK Stock?

Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is430.32 USD with a low forecast of 390.00 USD and a high forecast of 465.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Stryker Corp (SYK)'s revenue for the last quarter?

Stryker Corp revenue for the last quarter amounts to 6.02B USD, increased 2.63

What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?

Stryker Corp. EPS for the last quarter amounts to 1.93 USD, increased 14.20

How many employees does Stryker Corp (SYK). have?

Stryker Corp (SYK) has 56000 emplpoyees as of July 08 2026.

What is Stryker Corp (SYK) market cap?

Today SYK has the market capitalization of 126.41B USD.